Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline

RBC Capital Markets upgraded Neumora Therapeutics, Inc. (NASDAQ:NMRA) from Sector Perform to Outperform, with an increased price forecast from $4 to $7.The company is evolving beyond neurology and that is not reflected in market capitalization.Analyst Brian Abrahams on Monday wrote that Neumora is “positioning” itself well with a competitive early asset in an NLRP3 class demonstrating emerging promise across multiple large-market indications, including obesity and cardiometabolic disease.Data in 2026 “shoul ...